Jiaxin Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiaxin Jin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Junxu Zhu
Department of Orthopedics, The Second Hospital of Lanzhou University, The Second Clinical Medical School, Gansu Provincial Bone and Joint Research Institute, Lanzhou University, Lanzhou 730030, China
2 shared publications Tianci Yu
The Second Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of China
2 shared publications- Wenhao Guo
Department of Orthopedics, The Second Hospital of Lanzhou University, The Second Clinical Medical School, Gansu Provincial Bone and Joint Research Institute, Lanzhou University, Lanzhou 730030, China
2 shared publications - Zongyan Cai
The Second Clinical Medical College Lanzhou University Lanzhou China
2 shared publications - Zongyan Cai
Department of Orthopedics, The Second Hospital of Lanzhou University, The Second Clinical Medical School, Gansu Provincial Bone and Joint Research Institute, Lanzhou University, Lanzhou 730030, China
2 shared publications Chengwei Xing
The Second Clinical Medical College Lanzhou University Lanzhou China
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1206
Barrier-Guided Local Nanopharmaceutics for Cartilage and Osteochondral Regeneration: From Effective Tissue Exposure to Cell-State Control and Translational Quality Attributes
Local nanopharmaceutic systems are increasingly used to prolong intra-articular residence, improve cartilage access, control local release, and regulate repair-relevant cell states. However, joint retention is often mistaken for effective tissue exposure, and nanoscale complexity is frequently treated as an advantage without demonstrating which transport, biological, or mechanical barrier it resolves. This narrative review develops a barrier-guided framework for nanocarriers, nano-enabled hydrogels, extracellular vesicles, and spatial osteochondral constructs. We distinguish nominal formulation identity from the delivered material state that emerges after dilution, protein adsorption, mechanical loading, and degradation, and we separate joint-cavity persistence, cartilage partitioning and penetration, and bioavailable cargo at target cells. The evidence is strongest when a controllable material attribute is linked to a depth-resolved exposure or repair function; it remains uneven for coupled loading–release behavior, direct cross-platform comparisons, and transferable acceptance limits. We therefore distinguish published quantitative anchors from product-specific specifications and propose a staged workflow that defines two-sided failure boundaries for size and dispersity, binding–dissociation kinetics, stress relaxation, dose, and potency. Across platforms, the practical priorities are reversible rather than maximal binding, matched static-versus-loaded release testing, mechanism-necessity controls for extracellular vesicles, modality-aware fate measurements, and critical quality attributes linked to in vivo performance. The most credible strategy is the minimum necessary complexity that preserves a measurable structure–property–exposure–function relationship from manufacture through remodeling.
- 23 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1206
Open AccessBarrier-Guided Local Nanopharmaceutics for Cartilage and Osteochondral Regeneration: From Effective Tissue Exposure to Cell-State Control and Translational Quality Attributes
Local nanopharmaceutic systems are increasingly used to prolong intra-articular residence, improve cartilage access, control local release, and regulate repair-relevant cell states. However, joint retention is often mistaken for effective tissue exposure, and nanoscale complexity is frequently treated as an advantage without demonstrating which transport, biological, or mechanical barrier it resolves. This narrative review develops a barrier-guided framework for nanocarriers, nano-enabled hydrogels, extracellular vesicles, and spatial osteochondral constructs. We distinguish nominal formulation identity from the delivered material state that emerges after dilution, protein adsorption, mechanical loading, and degradation, and we separate joint-cavity persistence, cartilage partitioning and penetration, and bioavailable cargo at target cells. The evidence is strongest when a controllable material attribute is linked to a depth-resolved exposure or repair function; it remains uneven for coupled loading–release behavior, direct cross-platform comparisons, and transferable acceptance limits. We therefore distinguish published quantitative anchors from product-specific specifications and propose a staged workflow that defines two-sided failure boundaries for size and dispersity, binding–dissociation kinetics, stress relaxation, dose, and potency. Across platforms, the practical priorities are reversible rather than maximal binding, matched static-versus-loaded release testing, mechanism-necessity controls for extracellular vesicles, modality-aware fate measurements, and critical quality attributes linked to in vivo performance. The most credible strategy is the minimum necessary complexity that preserves a measurable structure–property–exposure–function relationship from manufacture through remodeling.
- Open Access
- 18 August 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (16) , 1021
Attapulgite Nanocomposites for Cartilage and Osteochondral Repair: Material–Tissue Matching, Evidence-Graded Mechanisms and Translation
Attapulgite (ATP; palygorskite) is a fibrous magnesium aluminum silicate that can reinforce hydrated polymer networks, provide a surface for molecular interactions, and participate in formulation-dependent ion or drug delivery. Although ATP has been studied most extensively in bone-oriented composites, its more distinctive role in cartilage repair may be as a spatially controlled regulator of the scaffold microenvironment rather than as a uniformly distributed bioactive filler. This review therefore examines ATP from a cartilage-first perspective. Direct ATP evidence, effects of modified ATP, performance of complete drug-loaded formulations, and cross-material extrapolations are considered separately. Current cartilage data support injectability, shear-thinning, photocrosslinking, mechanical reinforcement, and sustained intra-articular delivery but do not yet establish durable hyaline cartilage regeneration. In osteochondral constructs, ATP is more plausibly restricted to the calcified-cartilage interface or subchondral region, where reinforcement and mineral-associated functions may be beneficial, while high or uniform cartilage-side loading could increase stiffness, hypertrophy, or ectopic mineralization. This interpretation leads to testable design rules: define the ATP material fingerprint, map dose and spatial distribution, distinguish the true carrier phase, and assess cartilage matrix quality, lubrication, anti-hypertrophic stability, interface mechanics, persistence, and synovial safety. ATP should thus be developed as a dose-controlled and spatially restricted component whose value depends on material–tissue matching and direct mechanistic validation.
- 18 August 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (16) , 1021
Open AccessAttapulgite Nanocomposites for Cartilage and Osteochondral Repair: Material–Tissue Matching, Evidence-Graded Mechanisms and Translation
Attapulgite (ATP; palygorskite) is a fibrous magnesium aluminum silicate that can reinforce hydrated polymer networks, provide a surface for molecular interactions, and participate in formulation-dependent ion or drug delivery. Although ATP has been studied most extensively in bone-oriented composites, its more distinctive role in cartilage repair may be as a spatially controlled regulator of the scaffold microenvironment rather than as a uniformly distributed bioactive filler. This review therefore examines ATP from a cartilage-first perspective. Direct ATP evidence, effects of modified ATP, performance of complete drug-loaded formulations, and cross-material extrapolations are considered separately. Current cartilage data support injectability, shear-thinning, photocrosslinking, mechanical reinforcement, and sustained intra-articular delivery but do not yet establish durable hyaline cartilage regeneration. In osteochondral constructs, ATP is more plausibly restricted to the calcified-cartilage interface or subchondral region, where reinforcement and mineral-associated functions may be beneficial, while high or uniform cartilage-side loading could increase stiffness, hypertrophy, or ectopic mineralization. This interpretation leads to testable design rules: define the ATP material fingerprint, map dose and spatial distribution, distinguish the true carrier phase, and assess cartilage matrix quality, lubrication, anti-hypertrophic stability, interface mechanics, persistence, and synovial safety. ATP should thus be developed as a dose-controlled and spatially restricted component whose value depends on material–tissue matching and direct mechanistic validation.
- Open Access
- 5 July 2023
- Published by Wiley in Orthopaedic Surgery
- Vol. 15 (9) , 2244-2259
Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma
Osteosarcoma (OS) is a common malignant bone tumor that occurs mostly in children and adolescents. At present, surgery after chemotherapy or postoperative adjuvant chemotherapy is the main treatment plan. However, the efficacy of chemotherapeutic drugs is limited by the occurrence of chemotherapeutic resistance, toxicity to normal cells, poor pharmacokinetic performance, and drug delivery failure. The delivery of chemotherapy drugs to the bone to treat OS may fail for a variety of reasons, such as a lack of selectivity for OS cells, initial sudden release, short‐term release, and the presence of biological barriers (such as the blood‐bone marrow barrier). Nanomaterials are new materials with at least one dimension on the nanometer scale (1–100 nm) in three‐dimensional space. These materials have the ability to penetrate biological barriers and can accumulate preferentially in tumor cells. Studies have shown that the effective combination of nanomaterials and traditional chemotherapy can significantly improve the therapeutic effect. Therefore, this article reviews the latest research progress on the use of nanomaterials in OS chemotherapy.
- 5 July 2023
- Published by Wiley in Orthopaedic Surgery
- Vol. 15 (9) , 2244-2259
Open AccessResearch Progress of Nanomaterials in Chemotherapy of Osteosarcoma
Osteosarcoma (OS) is a common malignant bone tumor that occurs mostly in children and adolescents. At present, surgery after chemotherapy or postoperative adjuvant chemotherapy is the main treatment plan. However, the efficacy of chemotherapeutic drugs is limited by the occurrence of chemotherapeutic resistance, toxicity to normal cells, poor pharmacokinetic performance, and drug delivery failure. The delivery of chemotherapy drugs to the bone to treat OS may fail for a variety of reasons, such as a lack of selectivity for OS cells, initial sudden release, short‐term release, and the presence of biological barriers (such as the blood‐bone marrow barrier). Nanomaterials are new materials with at least one dimension on the nanometer scale (1–100 nm) in three‐dimensional space. These materials have the ability to penetrate biological barriers and can accumulate preferentially in tumor cells. Studies have shown that the effective combination of nanomaterials and traditional chemotherapy can significantly improve the therapeutic effect. Therefore, this article reviews the latest research progress on the use of nanomaterials in OS chemotherapy.
- Open Access
- 16 August 2022
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (1) , 1-12
Research Progress of Long Non-coding RNAs in Spinal Cord Injury
Spinal cord injury (SCI) can result in a partial or complete loss of motor and sensory function below the injured segment, which has a significant impact on patients' quality of life and places a significant social burden on them. Long non-coding RNA (LncRNA) is a 200–1000 bp non-coding RNA that has been shown to have a key regulatory role in the progression of a variety of neurological illnesses. Many studies have demonstrated that differentially expressed LncRNAs following spinal cord injury can participate in inflammatory damage, apoptosis, and nerve healing by functioning as competitive endogenous RNA (ceRNA); at the same time, it has a significant regulatory effect on sequelae such neuropathic pain. As a result, we believe that LncRNAs could be useful as a molecular regulatory target in the diagnosis, treatment, and prognosis of spinal cord injury.
- 16 August 2022
- Published by Springer Nature in Neurochemical Research
- Vol. 48 (1) , 1-12
Open AccessResearch Progress of Long Non-coding RNAs in Spinal Cord Injury
Spinal cord injury (SCI) can result in a partial or complete loss of motor and sensory function below the injured segment, which has a significant impact on patients' quality of life and places a significant social burden on them. Long non-coding RNA (LncRNA) is a 200–1000 bp non-coding RNA that has been shown to have a key regulatory role in the progression of a variety of neurological illnesses. Many studies have demonstrated that differentially expressed LncRNAs following spinal cord injury can participate in inflammatory damage, apoptosis, and nerve healing by functioning as competitive endogenous RNA (ceRNA); at the same time, it has a significant regulatory effect on sequelae such neuropathic pain. As a result, we believe that LncRNAs could be useful as a molecular regulatory target in the diagnosis, treatment, and prognosis of spinal cord injury.
- Open Access
- 3 March 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 820858
Non-Coding RNA Regulatory Network in Ischemic Stroke
Stroke is a worldwide public health problem that has caused a substantial economic burden to families and society. Despite recent major advances, there is still a need for more timely, effective diagnosis and treatment methods for acute ischemic stroke. Non-coding RNAs (ncRNAs), which widely exist in the human body, do not encode proteins. Instead, these mediate various cellular processes as functional regulatory molecules from the RNA level. Each ncRNA node in organisms is not isolated but constitutes a complex regulatory network, regulating multiple molecular targets and triggering specific physiological or pathological reactions, leading to different outcomes. Abundant studies have proclaimed the impact of ncRNAs in ischemic stroke, which may enlighten new inspirations for diagnosing and treating ischemic stroke. This paper outlines the current understanding of the ncRNA regulatory network and reviews the recent evidence for the contribution of ncRNAs in the experimental ischemic stroke model.
- 3 March 2022
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 820858
Open AccessNon-Coding RNA Regulatory Network in Ischemic Stroke
Stroke is a worldwide public health problem that has caused a substantial economic burden to families and society. Despite recent major advances, there is still a need for more timely, effective diagnosis and treatment methods for acute ischemic stroke. Non-coding RNAs (ncRNAs), which widely exist in the human body, do not encode proteins. Instead, these mediate various cellular processes as functional regulatory molecules from the RNA level. Each ncRNA node in organisms is not isolated but constitutes a complex regulatory network, regulating multiple molecular targets and triggering specific physiological or pathological reactions, leading to different outcomes. Abundant studies have proclaimed the impact of ncRNAs in ischemic stroke, which may enlighten new inspirations for diagnosing and treating ischemic stroke. This paper outlines the current understanding of the ncRNA regulatory network and reviews the recent evidence for the contribution of ncRNAs in the experimental ischemic stroke model.